



A. Weiß¹, D. Poddubnyy², U. Kiltz^{3,4}, D. Simon⁵, F. Behrens^{6,7}, X. Baraliakos^{3,4}, M. Rudwaleit⁸, A. Regierer¹

1 German Rheumatology Research Center, Program area Epidemiology and Health Services Research, Berlin, Germany, 2 University of Toronto and Schroeder Arthritis Institute, Division of Rheumatology, Toronto, Canada, 3 Ruhr Universität, Bochum, Germany, 4 Rheumazentrum Ruhrgebiet, Herne, Germany, 5 Charité – Universitätsmedizin Berlin, Berlin, Germany, 6 University Hospital Frankfurt, Rheumatology, Frankfurt, Germany, 7 Fraunhofer Institute ITMP, Frankfurt, Germany, 8 Universitätsklinikum Bielefeld, Bielefeld, Germany



EULAR 2026 – POS0190

anne.regierer@drfz.de www.rabbit-spa.de

KEY RESULTS

- 76% fulfill the 2009 criteria and 67% the 2025 criteria
- However, 20% do not fulfill the entry criteria (age<45 and chronic back pain ≥3 months)
- Most patients fulfil the imaging arm of the criteria
- In the 2025 criteria, only 3% of the patients fulfill the criteria via clinical arm

→ imaging is essential

AIM

To assess the performance of the

- 2009 ASAS classification criteria for axSpA and
- 2025 newly proposed ASAS-SPARTAN criteria within the RABBIT-SpA register

ACKNOWLEDGEMENT


RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Biogen, Celltrion, Janssen-Cilag, Lilly, Novartis, Pfizer, and UCB.

We thank all participating patients and rheumatologists.


METHOD

- Patient selection: all patients with axSpA diagnosis from RABBIT-SpA register
- All parameters from both criteria sets are available

2009 - ASAS Criteria for axSpA




2025 – ASAS-SPARTAN Criteria for axSpA




RESULTS

	2009	fulfilled	not fulfilled	
2025	fulfilled	1,507 (67%)	0	1,507 (67%)
	not fulfilled	191 (9%)	538 (24%)	729 (33%)
		1,698 (76%)	538 (24%)	2,236

RESULTS



2009 - ASAS Criteria for axSpA



2025 – ASAS-SPARTAN Criteria for axSpA



Baseline Parameter	N = 2.236
Females	44%
Age, mean	44.2
BMI >30	25%
≥3 Comorbidities	19%
Symptom duration years, mean	11.7
Disease duration years, mean	6.6
ASDAS, mean	2.8
BASDAI, mean	4.7
BASFI, mean	3.7
PhGA, mean	5.2
PtGA, mean	5.8

SpA Features	2.236 (100%)
HLA-B27	1.596 (71%)
IBP	2.084 (93%)
Arthritis	1.070 (48%)
Enthesitis	518 (23%)
Uveitis	360 (16%)
Psoriasis	284 (13%)
ASDAS, mean	133 (6%)
Elevated CRP	1.349 (60%)
Dactylitis	90 (4%)
NSAID response	1.506 (67%)
Family history for SpA	636 (28%)